Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK(+) ALCL: results of COG trial ANHL12P1

Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL) relapse. Although brentuximab vedotin has demonstrated excellent activity in ALCL, it has not been used for newly diagnosed patients. Children’s Oncology Group (COG) trial ANHL12P1 determined the toxicity and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowe, Eric J., Reilly, Anne F., Lim, Megan S., Gross, Thomas G., Saguilig, Lauren, Barkauskas, Donald A., Wu, Rui, Alexander, Sarah, Bollard, Catherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462406/
https://www.ncbi.nlm.nih.gov/pubmed/33684925
http://dx.doi.org/10.1182/blood.2020009806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462406/
https://www.ncbi.nlm.nih.gov/pubmed/33684925
http://dx.doi.org/10.1182/blood.2020009806

Ejemplares similares